The estimated Net Worth of Alan Kersey is at least $6.29 millió dollars as of 31 August 2005. Alan Kersey owns over 18,500 units of Illumina Inc stock worth over $6,064,491 and over the last 20 years Alan sold ILMN stock worth over $222,370.
Alan has made over 1 trades of the Illumina Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Alan sold 18,500 units of ILMN stock worth $222,370 on 31 August 2005.
The largest trade Alan's ever made was selling 18,500 units of Illumina Inc stock on 31 August 2005 worth over $222,370. On average, Alan trades about 9,250 units every 0 days since 2005. As of 31 August 2005 Alan still owns at least 48,582 units of Illumina Inc stock.
You can see the complete history of Alan Kersey stock trades at the bottom of the page.
Alan's mailing address filed with the SEC is 9885 TOWNE CENTRE DRIVE, , SAN DIEGO, CA, 92121.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley és Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: